Literature DB >> 11425690

Surgical excision of iris nodules in the management of sarcoid uveitis.

V V Ocampo1, C S Foster, S Baltatzis.   

Abstract

PURPOSE: To illustrate the role of surgical removal of iris nodules (granulomas) in the management of sarcoid uveitis. STUDY
DESIGN: Two interventional case reports.
METHODS: The authors describe the clinical course of two 10-year-old males with long-standing granulomatous uveitis refractory to medical antiinflammatory and immunomodulatory therapy. Both patients were seen with iris masses, which were excised and biopsied, with findings of sarcoidosis. MAIN OUTCOME MEASURES: Control of ocular inflammation as evidenced by decrease in inflammatory cells in both anterior and posterior chambers.
RESULTS: On excision of the iris masses, the ocular inflammation was controlled in both patients.
CONCLUSIONS: The authors hypothesize that iris granulomas may not only be products of persistent antigenic stimulation characteristic of sarcoidosis but subsequently become foci of continued cytokine production and ocular inflammation. Total surgical removal of the iris masses may help in the diagnosis and control of sarcoid uveitis refractory to medical management.

Entities:  

Mesh:

Year:  2001        PMID: 11425690     DOI: 10.1016/s0161-6420(01)00601-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  Iris nodules associated with infectious uveitis.

Authors:  T D Myers; J R Smith; A K Lauer; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

2.  A case of Listeria monocytogenes endophthalmitis with recurrent inflammation and novel management.

Authors:  Adam C Weber; Ashleigh L Levison; Sunil K Srivastava; Careen Y Lowder
Journal:  J Ophthalmic Inflamm Infect       Date:  2015-10-05

3.  Age-related differences in the clinical features of ocular sarcoidosis.

Authors:  Kei Takayama; Kozo Harimoto; Tomohito Sato; Yutaka Sakurai; Manzo Taguchi; Takayuki Kanda; Masaru Takeuchi
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.